159 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
pathophysiology. We intend to pursue an accelerated approval using frataxin levels, supportive pharmacodynamics and clinical information, and safety data from
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
Executive Officer of Larimar. “Additionally, the first patient in our OLE study has been dosed. The OLE study will inform on the long-term safety profile … of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics
8-K
EX-99.1
i00qyia5lqyk8 qe
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
11a0kl72tc fizx
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
urgsoqur6 zixlzc
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
xl310gfyy m3u
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
vb5z1t rapp1upbs
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
vb5odzfwn
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
3j98zs zou7jfv9u2
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
hlinsmy9r9vd t9v6a5
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
zb0l3hj577q3qx
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
ruy3h
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
7eb3ua5ent4joqgeicg
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
s09j39
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
84fmjmd0vj5wyvihfc5
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am